An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
NCT02281526
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
BIA 2-093
Sponsor
Bial - Portela C S.A.